Cargando…
Pre-surgical oncolytic virotherapy improves breast cancer outcomes
Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, contr...
Autores principales: | Mullins-Dansereau, Victor, Petrazzo, Grégory, Geoffroy, Karen, Béland, Delphine, Bourgeois-Daigneault, Marie-Claude |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791421/ https://www.ncbi.nlm.nih.gov/pubmed/31646102 http://dx.doi.org/10.1080/2162402X.2019.1655363 |
Ejemplares similares
-
Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer
por: Martin, Nikolas Tim, et al.
Publicado: (2019) -
Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
por: Gujar, Shashi A, et al.
Publicado: (2014) -
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
por: Roy, D. G., et al.
Publicado: (2021) -
Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers
por: Geoffroy, Karen, et al.
Publicado: (2023) -
Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy
por: Alvarez-Breckenridge, Christopher A., et al.
Publicado: (2013)